Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
EGFR resistance
EGFR tyrosine kinase inhibitors
NSCLC
Oncogene fusions
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
02
2020
accepted:
17
02
2020
entrez:
30
9
2021
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
Despite initial benefit, virtually all patients suffering from Patients with Six gene fusions were detected in tumor progression biopsies under an EGFR TKI from 62 consecutive patients (9.7%) with Oncogenic fusions at the time of EGFR TKI resistance were identified at a relatively high frequency, mainly after the third-generation TKI osimertinib. Patients progressing to EGFR TKIs may have a new opportunity for targeted therapy when oncogenic fusions are identified.
Identifiants
pubmed: 34589930
doi: 10.1016/j.jtocrr.2020.100023
pii: S2666-3643(20)30023-0
pmc: PMC8474286
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100023Informations de copyright
© 2020 The Authors.
Références
J Thorac Oncol. 2019 May;14(5):802-815
pubmed: 30831205
Oncogene. 2017 Jan 26;36(4):471-481
pubmed: 27345413
Cancer Discov. 2018 Dec;8(12):1529-1539
pubmed: 30257958
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nat Rev Clin Oncol. 2018 Nov;15(11):694-708
pubmed: 30108370
Cancer Manag Res. 2019 Jul 09;11:6343-6351
pubmed: 31372039
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
J Thorac Oncol. 2017 Dec;12(12):e202-e204
pubmed: 29169525
Ann Transl Med. 2018 Apr;6(8):142
pubmed: 29862231
Oncotarget. 2017 Mar 14;8(11):17795-17809
pubmed: 28147313
Genome Med. 2018 Mar 28;10(1):25
pubmed: 29592813
Lung Cancer. 2015 Sep;89(3):357-9
pubmed: 26187428
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644